QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=C86D728336018B8BD22287419A4B6176;jsessionid=E69F9014E9AEFB613331D776B0CB92CD;jsessionid=7034153A2587771F8BE12FEAF963B6A9;jsessionid=F5B98B2623B814408CF030B9808BE64B;jsessionid=7BF2AEC5E1286F9BB53BDB76A6A01359;jsessionid=3992D0F6D6C9C91734BA20D7B247DBA5 (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=2766B9A4379564671E9BCB65AB596CAF;jsessionid=A06FF884E94C89B37D11661C0B1FCC3D;jsessionid=C86D728336018B8BD22287419A4B6176;jsessionid=E69F9014E9AEFB613331D776B0CB92CD;jsessionid=7034153A2587771F8BE12FEAF963B6A9;jsessionid=F5B98B2623B814408CF030B9808BE64B;jsessionid=7BF2AEC5E1286F9BB53BDB76A6A01359;jsessionid=3992D0F6D6C9C91734BA20D7B247DBA5